{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-023269","form_type":"8-K","ticker":null,"cik":"0001907685","company_name":"Comera Life Sciences Holdings, Inc.","filed_at":"2023-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.564715+00:00","generated_at":"2026-06-14T20:08:37.163248+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Comera Life Sciences receives Nasdaq delisting notice for failing MVLS standard","bullets":["Received Nasdaq determination letter on May 18, 2023 for non-compliance with $35M MVLS minimum.","Grace period ended May 17, 2023; stock had not achieved $35M MVLS for 10 consecutive days.","Must request hearing by May 25, 2023 to appeal; otherwise delisting on May 30, 2023.","Company intends to request a hearing; trading will continue until Panel decision.","If delisted, common stock expected to trade on OTC Markets Group."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-023269","json":"https://secwatch.observer/filing/0000950170-23-023269.json","markdown":"https://secwatch.observer/filing/0000950170-23-023269.md","text":"https://secwatch.observer/filing/0000950170-23-023269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907685/000095017023023269/0000950170-23-023269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907685/000095017023023269/cmra-20230518.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T20:08:37.163248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dcd60b75527f704673e585a406ff0013634c1bae","claim":"Comera Life Sciences Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"May 18, 2023, Comera Life Sciences Holdings, Inc. (the “Company”) received a determination letter (the “Letter”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has not regained compliance with the Market Value of Listed Securities (“MVLS”) Standard, since the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MLVS Rule”) and had not been at least $35 million for a minimum of 10 co","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1907685/000095017023023269/0000950170-23-023269-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}